

UPDATES ON LABORATORY DIAGNOSIS OF TB

BY

DR KARTINA MD NOOR

CLINICAL MICROBIOLOGIST

HOSPITAL SULTAN ABDUL HALIM, KEDAH

OUTLINE

- Introduction
- Updates on pre analytical area
- Smear and related tests
- Identification and drug sensitivity testing

INTRODUCTION


- TB is a global health problem
- 2013 9 million people had TB and 1.5 million died.
- Estimated 480 000 developed multi drug resistant TB (MDR TB)
- Majority diagnosed by smear microscopy on sputum specimen at the peripheral microscopy centres.
- Several diagnostic tests endorsed by WHO over the last eight years.

TB DIAGNOSTIC GAP

- More effective diagnostics available near patients' care.
- Growing pipeline of new TB diagnostics due to more funds from multinational donors and high burden countries with flourishing economies.
- Market reports showed more than USD 1 billion was spent on TB diagnostics in 2004.
- 83 million smear microscopy tests and 47 million chest X-rays
- US\$480 million spent in 2013 on TB test alone in 4 countries...


COMMERCIAL INCENTIVES FOR NEW DIAGNOSTICS

Global TB report WHO 2013



■ Other countries ■ India ■ China ■ South Africa ■ Brazil

Estimated TB incidence rates, 2013



PRIORITIES FOR NEW TB DIAGNOSTICS

- **Rapid sputum based test to detect TB with/without drug sensitivity**
- **Rapid non-sputum based test to detect all forms of TB at point of care**
- **Community based triage test for use by first contact health care providers to identify persons who need further testing**

CURRENT AVAILABLE TESTS IN MALAYSIA (MOH)

- Health clinics – sputum microscopy (ZN or Auramine stain)
- State or regional hospitals – Microscopy and culture (Gene Xpert)
- Regional Public Health Lab – Culture and Line Probe Assay
- National Public Health Lab – Culture PCR Line

DRUG SENSITIVITY TEST IN ONE LABORATORY ONLY??

- **Dedicated infrastructure – biosafety level 3**
- **Because handling large bacterial load**
- **Dedicated and trained staff**
- **Fully maintained laboratory**

LIGHT VS FLUORESCENT MICROSCOPY

- 5 minutes / slide
- 1000x magnification
- Light microscope
- 40-80% sensitivity
- 40 cents per slide
- 1 minute /slide
- 200x and 400x magnification
- LED microscope
- 10% increased in sensitivity
- RM4 per slide

SOLID CULTURE VS BROTH CULTURE (MGIT)


- Total incubation 8 weeks before **NO GROWTH**
 - Positive growth observed after 3 weeks
 - Manually observe tube for growth every week
 - Contamination rate 5%
 - RM 4 per bottle
- Total incubation 6 weeks
 - Positive growth after 1 week
 - Automated. Incubator will alert
 - Higher risk of aerosolisation

SOLID CULTURE

VS

LIQUID


CULTURE



COMMERCIAL NAAT: GENE XPERTS

- 14 Gene Xperts in MOH hospitals
- WHO endorsed IN 2010
- Use limited to
 1. ?MDR
 2. Contact of MDR patient
 3. Paediatrics TB patient
 4. HIV with ?TB
 5. Extrapulmonary sample
- Minimum sample handling
- Need continuous air conditioned room

GENEXPERT



GENEXPERT

Rifampin susceptible sample



Assay Name: 01
 Sample ID: 2009418-15-02-01
 Assay: MTB Beta
 Assay Version: 3.1
 Assay Type: Rifampin Susceptibility
 Agent Lot ID: 80602
 Cartridge SM: 3
 Installation Date: 2009
 Test Type: Specimen

Views
 Result View
 MTB Beta Assay
 Temperature-Sample
 Optic-All Options
 Optic-Primary
 Pressure
 Optic-Primary-Three
 2nd Derivative

Legend
 Probe D, Primary
 Probe C, Primary
 Probe E, Primary
 Probe B, Primary
 Ig, Primary
 Probe A, Primary

Notes
 Start Time: 2009/11/15 09:23
 End Time: 2009/11/15 17:15:01
 Status: Done
 Error Status: OK
 Show Report
 Assay Version: 3.1
 Instrument Model SM: 782200604 01.2

Test and Analyte Result | Detail | Trends | History | Messages
 Assay Name: MTB Beta | Version: 3
 Test Result: **POSITIVE (Rifampin)**
 All Analytes: MDR (Rifampin)

Analyte Name	CT	Shift	Analyte Result	Probe Check Result
Probe D	13.1	148.0	POS	PASS
Probe C	12.3	173.0	POS	PASS
Probe E	13.4	174.0	POS	PASS
Probe B	13.0	174.0	POS	PASS
Ig	37.4	148.0	NA	PASS
Probe A	12.3	173.0	POS	PASS

LINE PROBE ASSAY (HAIN)

- Need positive smear
 - WHO endorsed
 - Manual and automated
 - From patient sputum samples or culture isolates
1. Detection of MTB complex
 2. Detection of MTB complex with rif / isoniazid resistance
 3. Detection of MTB complex with resistance to fluroquinolones, aminoglycoside, cyclic peptides, and ethambutol



LINE PROBE ASSAY

- From Mycobacterium cultures
 1. Identification of MTB complex
 2. Identification of MTB complex and 27 Non Tuberculous Mycobacterium (NTM)
 3. Identification of further 19 NTMs

Performance Comparisons

	LPA	GeneXpert
Require 3 rooms	Yes	No <input checked="" type="checkbox"/>
Dedicated equipment	Yes	Yes <input checked="" type="checkbox"/>
Stock control	Complex	Simple <input checked="" type="checkbox"/>
Need for BSC	Yes	??No <input checked="" type="checkbox"/>
TAT	≈ 1-2 days	≈2 hrs <input checked="" type="checkbox"/>
Test complexity	Very	Simple <input checked="" type="checkbox"/>
Requires processed sputum	Yes	No <input checked="" type="checkbox"/>
Sensitivity in Sm-/Cult+	≈20%	≈75% <input checked="" type="checkbox"/>
Recommended for Sm- specimens	No	Yes <input checked="" type="checkbox"/>
Recommended for extrapulmonary TB	No	Limited <input checked="" type="checkbox"/>
INH resistance	Yes <input checked="" type="checkbox"/>	No
Second-line DST	Yes <input checked="" type="checkbox"/>	No
Interpretation of results	Challenging	Computerised <input checked="" type="checkbox"/>


LINE PROBE ASSAY (LPA)



WHAT IS NEW?

Global TB diagnostic pipeline

Early Development Late or Commercial Development On Pathway to being first used

	<p>Early Development</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>	<p>Late or Commercial Development</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>	<p>On Pathway to being first used</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>
<p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>	<p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>	<p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>	<p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>
<p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>	<p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>	<p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>	<p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p> <p>Targeting TB across all TB subtypes - drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB)</p>

DIAGNOSTIC TESTS RECENTLY ENDORSED BY WHO

- Urine LAM (Alere) in 2015
- TB LAMP (Eiken) in 2016

LAM


- Antigen test for urine
- Lipoarabinomannan (LAM) found in growing mycobacterium cell wall
- Released in blood and subsequently in urine
- Sensitivity of the test correlates with low CD4 count.
- Only useful in AIDS cases

Urinary LAM (Alere Determine) as a screening test for TB in HIV positives with low CD4 cell counts?



Lawn, SD et al 2012

Sensitivity of TB LAM in HIV-TB co-infected patients




Peter, JG et al 2012


Against composite RS	Sensitivity (%)	Specificity (%)
All patients	45	96
CD4 > 200	29	100
CD4 ≤ 200	52	94

Dorman, S et al 2012

Performance of TB LAM in HIV-TB co-infected patients



Shah, M et al 2012



LAM – URINE TEST

The screenshot shows a presentation slide titled "LAM - a niche test" with a WHO logo. The slide content includes:

The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV

POLICY GUIDANCE

NEW DIAGNOSTIC TESTS | DIAGNOSIS RECOMMENDATIONS
EXTRA PULMONARY TB | TUBERCULOSIS
TB/HIV | TB URINE TEST
RAPID TESTS | PERFORMANCE | MYCOBACTERIUM HIV LOW CD4

Niche test: Only a subset of patients benefits

World Health Organization

Box 5.1 WHO recommendations on urine lateral flow lipoarabinomannan (LF-LAM) assay (Alere Determine TB LAM Ag test, Alere Inc, USA)

The 2015 WHO recommendations on LF-LAM assay are:

1. LF-LAM **should not** be used for the diagnosis of TB, *except as specifically described below for persons with HIV with low CD4 counts or who are seriously ill^a* (strong recommendation; low quality of evidence).
2. LF-LAM **may be used to assist** in the diagnosis of TB in HIV-positive adult *inpatients* with signs or symptoms of TB (pulmonary and/or extrapulmonary) who have a CD4 cell count less than or equal to 100 cells/ μ L, or HIV-positive patients who are seriously ill^a regardless of CD4 count or with unknown CD4 count (conditional recommendation; low quality of evidence).
3. LF-LAM **should not be used** as a screening test for TB (strong recommendation; low quality of evidence).

Remarks

- This recommendation also applies to HIV-positive adult *outpatients* with signs and symptoms of TB (pulmonary and/or extrapulmonary) who have a CD4 cell count less than or equal to 100 cells/ μ L, or HIV-positive patients who are seriously ill^a regardless of CD4 count or with unknown CD4 count, based on the generalisation of data from inpatients.
- This recommendation also applies to children, based on the generalisation of data from adults while acknowledging very limited data and concern regarding the low specificity of the LF-LAM assay in children.

^a "seriously ill" is defined based on four danger signs: respiratory rate > 30/min, temperature > 39 °C, heart rate > 120/min and unable to walk unaided.

Click on Sign to add text and place signature on a PDF File.

TB LAMP (EIKEN)

- Manual molecular test
- Feasible to be implemented in peripheral microscopy lab
- Relatively high throughput
- Do not require sophisticated instrumentation
- Biosafety requirements similar to those performing sputum smear microscopy
- May be used as replacement to smear microscopy or adjunct to smear microscopy in smear negative samples
- Available in China, South Korea, Taiwan, Thailand and Japan (August 2016)

LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP)

- Amplification and detection on gene completed in a single step by incubating mixture of sample, primers, DNA polymerase with strand displacement activity and substrates at constant temperature 69°C
- Reagents located at the cap of reaction tubes
- Detection by fluorescence dye

Sample preparation




Heating tube




Block 90° C for 5 min

DNA extraction (PURE)



Adsorbent tube
Injection cap

Amplification (LAMP reaction)



Close lids and let stand upside down for 2 min; then mix



67° C for 40 min

Detection



Fluorescent signal detection



**DEVELOPMENTS IN OTHER AREAS?
STILL UNDERGOING VALIDATION...**


IMPROVEMENT IN SAMPLE COLLECTION

- Major persistent problem with collection of adequate specimen when patient unable to provide sufficient volume of specimen
- Sputum induction may need additional effort, cost and increased risk to the medical personnel
- New product: Lung Flute from Medical Acoustics (USA)
- Non-invasive, user holds a small plastic device to their lips and exhale into it. This creates vibrations in the lungs that help to loosen and liquefy sputum in the alveolar cavities.
- Sensitivity hypertonic saline vs Lung flute is 78.4% and 84.3%

MAINTAINING SPECIMEN IN OPTIMAL CONDITION

- Product are being developed to liquefy and decontaminate sample allowing it to be transported without cold chain
- Allow transport of samples up to 8 days without cold chain
- Significant reduction in culture contamination fom 13% to 0%

AUTOMATED MICROSCOPY




Automating smear microscopy



RAPID SCREENING OF TB INFECTION AT POINT OF CARE: VOLATILE COMPOUNDS

- Proven by giant pouch rats which can accurately predict active PTB by sniffing sputum specimens
- Still in early developments
- eNose undergoing validation studies in Bangladesh, Indonesia Kenya, South Africa and Venezuela

Overview of the processes involved in breath testing.



[Konvalina and Haick 2014]



Metal-oxide-based olfactory sensor
Bruins et al. 2013]



Cough/aerosol collection combined with immunoassay based antigen detection
[McNerney et al. 2010]




Portable GC coupled to surface acoustic wave (SAW) detector
[Phillips et al. 2013] in a spectrometer
[Jassal et al. 2010]



¹³C-urea is converted to ¹³CO₂ in the patients lung if bacteria is present and detected
[Jassal et al. 2010]



New sensors based on array of chemical films: VOC leads to changes in electrical conduction



Ligand coated monolayer gold nanoparticles to analyze breath (in an adhesive patch)




Colorimetric sensor array for odour visualization.

Proof-of-principle data from feasibility studies available for some technologies (performance thus far not meeting TPP, limited independent study data)

SMELL THE TB



Intended laboratory location and release date (actual or anticipated)



MOLECULAR DETECTIONS /DST

- Genedrive (Epistem)
- Truelab(Molbio)
- Expert Ultra

All are in late or completed development and available in some countries

Awaiting WHO endorsement

MICROARRAY-BASED PLATFORMS

- Oligonucleotide capture probes are printed as clearly defined spots on a surface
- Their smaller size enables more spots to be printed to detect amplified target DNA
- Offer greater discriminatory power to a wider variety of drug resistance markers in a single test format
- Many are used in research purposes as yet.

CONCLUSION

- The last two decades showed tremendous progress in TB diagnostic tests
- Simpler, faster and cheaper test are needed and being developed to diagnose TB and MDR TB at the point of care testing
- TB has been here for a very long time and we will never win IF

**WE KEPT BRINGING A
KNIFE TO A GUNSHOT
FIGHT**

THANK YOU